Cargando…

Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect

Many drugs commonly prescribed during pregnancy lack a fetal safety recommendation – called FDA ‘category C’ drugs. This study aims to classify these drugs into harmful and safe categories using knowledge gained from chemoinformatics (i.e., pharmacological similarity with drugs of known fetal effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Boland, Mary Regina, Polubriaginof, Fernanda, Tatonetti, Nicholas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634437/
https://www.ncbi.nlm.nih.gov/pubmed/28993650
http://dx.doi.org/10.1038/s41598-017-12943-x
_version_ 1783270090544775168
author Boland, Mary Regina
Polubriaginof, Fernanda
Tatonetti, Nicholas P.
author_facet Boland, Mary Regina
Polubriaginof, Fernanda
Tatonetti, Nicholas P.
author_sort Boland, Mary Regina
collection PubMed
description Many drugs commonly prescribed during pregnancy lack a fetal safety recommendation – called FDA ‘category C’ drugs. This study aims to classify these drugs into harmful and safe categories using knowledge gained from chemoinformatics (i.e., pharmacological similarity with drugs of known fetal effect) and empirical data (i.e., derived from Electronic Health Records). Our fetal loss cohort contains 14,922 affected and 33,043 unaffected pregnancies and our congenital anomalies cohort contains 5,658 affected and 31,240 unaffected infants. We trained a random forest to classify drugs of unknown pregnancy class into harmful or safe categories, focusing on two distinct outcomes: fetal loss and congenital anomalies. Our models achieved an out-of-bag accuracy of 91% for fetal loss and 87% for congenital anomalies outperforming null models. Fifty-seven ‘category C’ medications were classified as harmful for fetal loss and eleven for congenital anomalies. This includes medications with documented harmful effects, including naproxen, ibuprofen and rubella live vaccine. We also identified several novel drugs, e.g., haloperidol, that increased the risk of fetal loss. Our approach provides important information on the harmfulness of ‘category C’ drugs. This is needed, as no FDA recommendation exists for these drugs’ fetal safety.
format Online
Article
Text
id pubmed-5634437
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56344372017-10-18 Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect Boland, Mary Regina Polubriaginof, Fernanda Tatonetti, Nicholas P. Sci Rep Article Many drugs commonly prescribed during pregnancy lack a fetal safety recommendation – called FDA ‘category C’ drugs. This study aims to classify these drugs into harmful and safe categories using knowledge gained from chemoinformatics (i.e., pharmacological similarity with drugs of known fetal effect) and empirical data (i.e., derived from Electronic Health Records). Our fetal loss cohort contains 14,922 affected and 33,043 unaffected pregnancies and our congenital anomalies cohort contains 5,658 affected and 31,240 unaffected infants. We trained a random forest to classify drugs of unknown pregnancy class into harmful or safe categories, focusing on two distinct outcomes: fetal loss and congenital anomalies. Our models achieved an out-of-bag accuracy of 91% for fetal loss and 87% for congenital anomalies outperforming null models. Fifty-seven ‘category C’ medications were classified as harmful for fetal loss and eleven for congenital anomalies. This includes medications with documented harmful effects, including naproxen, ibuprofen and rubella live vaccine. We also identified several novel drugs, e.g., haloperidol, that increased the risk of fetal loss. Our approach provides important information on the harmfulness of ‘category C’ drugs. This is needed, as no FDA recommendation exists for these drugs’ fetal safety. Nature Publishing Group UK 2017-10-09 /pmc/articles/PMC5634437/ /pubmed/28993650 http://dx.doi.org/10.1038/s41598-017-12943-x Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Boland, Mary Regina
Polubriaginof, Fernanda
Tatonetti, Nicholas P.
Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect
title Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect
title_full Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect
title_fullStr Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect
title_full_unstemmed Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect
title_short Development of A Machine Learning Algorithm to Classify Drugs Of Unknown Fetal Effect
title_sort development of a machine learning algorithm to classify drugs of unknown fetal effect
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634437/
https://www.ncbi.nlm.nih.gov/pubmed/28993650
http://dx.doi.org/10.1038/s41598-017-12943-x
work_keys_str_mv AT bolandmaryregina developmentofamachinelearningalgorithmtoclassifydrugsofunknownfetaleffect
AT polubriaginoffernanda developmentofamachinelearningalgorithmtoclassifydrugsofunknownfetaleffect
AT tatonettinicholasp developmentofamachinelearningalgorithmtoclassifydrugsofunknownfetaleffect